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Abstract  
Purpose: Clear cell Renal Cell Carcinomas (ccRCC), the largest group of renal 
tumours, are resistant to classical therapies. The determination of the functional state of 
actionable biomarkers for the assessment of these adenocarcinomas is essential. The 
dysregulation of the oncoprotein, PKB/Akt has been linked with poor prognoses in 
human cancers.  
Material & Methods: We analysed the status of the PKB/Akt pathway in a 
representative tumour tissue microarray obtained from the primary tumours and their 
metastases in 60 ccRCC with long term follow up. We sought to define the evolution of 
this pathway from the primary tumour to the metastatic event and to know the impact of 
its functional state in tumour aggressiveness and patient survival. Two-site time 
resolved amplified FRET (A-FRET) was utilised for assessing the activation state of 
PKB/Akt and this was compared to conventional immunohistochemistry measurements.  
Results: Activation state of PKB/Akt in primary tumours defined by A-FRET 
correlated with poorer overall survival (hazard ratio 0.228; p=0.002). Whereas, 
increased protein expression of phosphoPKB/Akt, identified using classical 
immunohistochemistry, yielded no significant difference (hazard ratio 1.390; p=0.548).  
Conclusions: Quantitative determination of PKB/Akt activation in ccRCC primary 
tumours alongside other diagnostics tools could prove key in taking oncologists closer 
to an efficient personalised therapy in ccRCC patients. 
General Significance 
The quantitative imaging technology based on Amplified-FRET can rapidly analyse 
protein activation states and molecular interactions. It could be used for prognosis and 
assess drug function during the early cycles of chemotherapy. It enables evaluation of 
clinical efficiency of personalised cancer treatment. 
  
 
Key Words: Clear Cell Renal Cell Carcinoma; Protein Kinase B (PKB/Akt); Amplified 
FRET; prognosis; FRET-FLIM; biomarker activation 
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INTRODUCTION 
 
Clear cell renal cell carcinomas (ccRCCs) are a major health concern in the West as 
they are quite a common aggressive radio- and chemo-resistant neoplasm [1]. Only 
surgery has demonstrated a signiﬁcant impact in patient survival, the 5-year overall 
mortality of this neoplasm is still reaching around 40% [2]. Truncal mutations in the Von 
Hippel–Lindau VHL tumor suppressor gene are the hallmark of this pathology, but 
therapies against this target have elicited, to date, only partial responses. These 
disappointing results are mainly related to the inherent high intratumoral heterogeneity 
(ITH) that ccRCCs display to the point that ITH is nowadays a major obstacle to the 
implementation of efficient therapies impacting significantly on patient survival [3]. 
The aim of this study is to determine whether the phosphoinositide 3-kinase 
(PI3K)/protein kinase B (PKB/Akt) dysregulation is implicated in the mechanisms 
underlying ccRCC carcinogenesis and its hypothetical impact on patient survival. To 
pursue this investigation a recently developed approach was utilised to determine the 
functional status of the PKB/Akt signaling pathway [4]. 
 
Protein kinase B (PKB/Akt) is a kinase from the AGC kinase superfamily which 
promotes cell growth, survival and proliferation [5, 6]. Upon the binding of a growth 
factor receptor to a receptor tyrosine kinase, phosphatidylinositol 4,5-bisphosphate 
(PtdIns(4,5)P2) is phosphorylated, by phosphoinositide 3-kinase (PI3K) to 
phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3). This transient formation of 
PtdIns(3,4,5)P3 recruits PKB and phosphoinositide-dependent protein kinase 1 (PDK1) 
to the plasma membrane. Upon the change in conformation of PKB, PDK1 
phosphorylates threonine-308 to partially active it [7, 8]. Full activation is achieved by m-
TOR  in complex 2 which phosphorylates serine 473 [9]. An overview of the PKB 
signalling pathway is shown in Figure 1.  PKB is known to be dysregulated in many 
human cancer [5]. This dysregulation can occur via the loss of inhibition through 
phosphatase and tensin homolog (PTEN) for example, or through the upregulation of 
the PI3K-Akt pathway [6, 10, 11]. Alternatively, a mutation of PKB itself could cause 
dysregulation within this pathway [12]. 
Currently, the use of fluorescent microscopy to detect protein expression is based on 
measuring the intensity and therefore proves to be imprecise; as well as lacking a 
dynamic range for providing a detailed view on the activation state of oncoproteins in 
the diagnosis and prognosis of various cancers. Assessing the expression levels of 
proteins does not provide information on the activation states of the protein in the 
advancement of a cancer. This is important as expression levels and activation states of 
oncoproteins do not necessarily correlate [4, 13]. Our method uses amplified Förster 
Resonance Energy Transfer (FRET), detected by a multiple frequency domain 
fluorescent lifetime imaging microscopy (mf FLIM), to assess the activation of different 
oncoproteins in primary and metastatic tumours of the same patients. It has been 
previously shown that this method, when used to assess PKB activation in breast 
tumors, correlated a higher PKB activation with a worse prognosis [4].  
 
The principles of FRET involve the non-radiative transfer of energy from one 
chromophore to another via dipole-dipole interactions at a distance equal to or less than 
10nm. An appropriately selected donor chromophore must have an emission spectrum 
that overlaps with the excitation spectrum of the chosen acceptor chromophore. When 
excited in the presence of an acceptor, the lifetime of a donor is decreased due to the 
depopulation of its excited state, where its energy is non-radiatively transferred to the 
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acceptor chromophore [14]. The fluorescent labelling of PKB on both serine and 
threonine sites will experience FRET upon the increase in the activation state of 
PKB/Akt.  
Exploiting this quantitative methodology has enabled us to show that the PKB/Akt 
activation in ccRCC primary tumours alongside other diagnostics tools could prove key 
in taking oncologists closer to an efficient personalised therapy in ccRCC patients. 
 
 
MATERIALS AND METHODS 
 
The authors declare that all the experiments carried out in this study comply with 
current Spanish and European Union legal regulations. Samples and data from patients 
included in this study were obtained from the medical records and archives of the 
Pathology Lab (Cruces University Hospital). All patients were informed about the 
potential use for research of their surgically resected tissues, and accepted this 
eventuality by signing a specific document. This study was approved by the Ethical and 
Scientific Committee (CEIC-Euskadi PI2015060). 
 
 
Patient samples 
Two experienced uropathologists (RG, JIL) performed the pathological analysis, re-
assigned grade and stage to all tumours and selected the appropriate tumour areas for 
analysis, including them in tumour microarrays (TMAs). The International Society of 
Urological Pathology (ISUP) 2013 tumour grading system [15] was assigned to every 
sample in the TMA on routine haematoxylin and eosin sections. Grade was grouped as 
low (G1/2) and high (G3/4) for higher consistency. UICC 2010 tumour staging system 
[16] was assigned to every case at the time of pathological diagnoses on nephrectomy 
specimens. Staging was grouped as pT1/2 (tumours confined to the kidney) and pT3 
(tumours invading outside the kidney).  
 
TMA preparation 
In every case, well preserved tumour areas of the highest grade, both in the primary 
tumour and its metastasis, were selected for analysis. Samples of 2.5 mm in diameter of 
these areas were obtained from the paraffin blocks and placed randomly in TMAs in a 
routine way to ensure a blind evaluation. Internal controls were included in all TMAs. 
Unstained 4 micron-thick samples of TMAs were mounted on slides ready for FRET 
analysis. 
 
Antibodies and reagents 
Monoclonal antibodies, rabbit anti-pAkt and mouse anti-panAkt were purchased from 
Cell Signalling Technology. Pierce endogenous peroxidase suppressor was also 
obtained from Thermo Fisher Scientific (catalogue no. 35000). AffiniPure F(ab’)2 
fragment donkey anti-rabbit IgG and peroxidase-conjugated AffiniPure F(ab’)2 fragment 
donkey anti-rabbit IgG were purchased from Jackson Immuno Research Laboratories. 
ATTO 488 NHS ester was purchased and was conjugated to the AffiniPure F(ab’)2 IgG 
as described in [4]. Prolong diamond anti-fade mount (catalogue no. P36970), bovine 
serum albumin (BSA) blocking reagent, amplification buffer and tyramide were all 
obtained from Life Technologies (catalogue nos. T20915COMPONENT - D, E and A).  
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 5 
Förster resonance energy transfer (FRET) by fluorescence lifetime imaging 
microscopy (FLIM) 
Two-site amplified FRET assay for PKB/Akt activation quantification. The slides 
underwent de-waxing and rehydration followed by heat antigen retrieval in Tris-EDTA 
(pH 9.0) buffer. Slides were incubated with peroxidase suppressor for 30 minutes. 
Afterwards slides were incubated for 1 hour with fresh 1% (10mg/ml) BSA blocking 
buffer. Following this the slides were incubated overnight at 4oC with the primary 
antibodies (pan-Akt 1:50, p-Akt 1:100). For secondary antibody labelling, donor only 
slides were incubated with Fab-ATTO488 (1:100) and donor acceptor slides with Fab-
ATTO488 (1:100) and Fab-HRP (1:200) for 2 hours at room temperature. Tyramide 
signal amplification was carried out on donor/acceptor slides. Fab-HRP is bound to the 
primary acceptor antibodies. Tyramide which is conjugated to Alexa594 is then added 
which, in the presence of H2O2, leads to the binding of the Alexa594 chromophore to the 
HRP molecule, thus fluorescently labelling the acceptor site. Slides were mounted with 
Prolong Diamond anti-fade mount.  
 
Analysis of biomarker activation using multiple frequency domain FLIM 
Immunohistochemistry (IHC) and immunofluorescence (IF) both operate around a one-
site assay whereas A-FRET employs the use of a two-site assay. A one-site assay 
detects only one antigen site at a time and induces non-specificity. A two-site assay 
detects two antigen sites simultaneously hence rendering an augmented precision. The 
conjugation of the chromophores to Fab fragments, which bind to the two primary 
antibodies, allowed the critical FRET distance of 10nm or less to be kept and provided a 
suitable tool for measuring the activation state of a given biomarker. To detect the 
signal of a sample with good precision and overcome autofluorescence, especially in 
fixed tissue samples, a signal to noise ratio of at least 4-fold must be observed. To 
achieve this, tyramide signal amplification was carried out.  
Using a high throughput mfFLIM (FASTBASE SOLUTIONS Ltd and Lambert 
Instruments), a mapping file was created semi-automatically which mapped each 
tumour core according to its position on the slide. Mapping the whole tumour core 
allowed each sample to be analysed completely rather than using segmental analysis. 
Images and results were automatically acquired from the arrays according to their 
positioning. Phase, lifetimes and average intensities were all calculated automatically 
and saved as an excel file, as well as lifetime images.  
 
Statistical Analysis 
Statistical analysis was performed using the GraphPad Prism software to create Kaplan-
Meier survival curves and Origin Pro8 used to provide statistical analysis and generate 
box and whisker plots. Statistical differences were calculated between groups using the 
Mann-Whitney U test (values indicated within the box and whisker plots). The Mann-
Whitney U test is a nonparametric test which does not assume a normal distribution of 
results. P values ≤ 0.05 indicated a statistical difference from the null hypothesis. Box 
and whisker plots represent the 25-75% range (box) and the 1-99 range (whiskers). 
Statistical differences are indicated with p values ≤ 0.05. For Kaplan-Meier survival 
curves, overall survival was plotted, which calculated a patient’s time from diagnosis 
until death or until the patient was last seen. The hazard ratio was also calculated for 
each Kaplan-Meier curve. Multivariate analysis was also performed to exclude 
influences among the evaluated parameters. A non-parametric Mann-Whitney U test 
was also used to see if there was correlation between different parameters and FRET 
efficiency or intensity and plotted as a Mann-Whitney plot. 
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RESULTS 
 
Patient data 
The series includes 60 patients diagnosed, treated and followed in the Cruces University 
Hospital from 1990 to 2014. Males predominated in the series (46M/14F) with an 
average age of 58.5 years (range 25-83). Primary tumours were located in the right 
kidney in 29 cases and in the left kidney in 31 cases. The average tumour diameter was 
8.5 cm (range 2-19). Thirty-two primary tumours were organ confined (pT1 and pT2) at 
the time of diagnosis. Twenty-five cases were low grade tumours (grades G1/2) and 35 
were high grade (grades G3/4). At the time when the follow-up was closed (Dec 2015), 
40 (66.6%) patients had died of disease. The average clinical follow up was 67.5 
months (range 1-240). The elapsed time between the diagnosis of the primary tumour 
and the metastasis widely oscillated, from 0 to 204 months. Epithelial organs, mostly 
lung and pancreas, were the sites of the metastatic seed in 29 cases (48.3%), lymph 
nodes in 13 cases (21.6%) and soft tissues/bone in 18 cases (30%). 
 
Figure 2A shows haematoxylin and eosin staining’s for typical low (left hand panel) and 
high (right hand panel) grade ccRCC samples. ISUP grading system [7] was assigned to 
every sample in the TMA. Samples were grouped as low (G1/2) and high (G3/4) grades 
for higher consistency.  Figure 2B shows fluorescent intensity maps and lifetime maps 
for the primary (left hand panel) and metastatic (right hand panel) tumour samples of 
one patient. The two-site assay was used to label pan Akt and pThr308-Akt 
simultaneously for each patient sample. The donor and acceptor intensity images 
indicate PKB/Akt and pThr308-Akt expression levels respectively. These images were 
equivalent to IHC images where little difference was observed between the primary and 
metastatic samples. Conversely, in the lifetime maps, a clear difference was observed 
between the samples, where lower lifetimes (see pseudo-colour scale) were indicative of 
higher PKB/Akt activation state. Some difference in fluorescence lifetime can be 
observed between the donor only samples of the primary and metastatic tumours of each 
patient however comparisons should be made between the donor and donor/acceptor of 
the same patient. Figure 2C shows the primary and metastatic PKB/Akt activation state 
for all patients determined by A-FRET. Some patients, such as patient 56, had a 
negligible PKB/Akt activation state in the primary tumour FRET Efficiency (Ef) =0%. 
However, the FRET efficiency increased to 44.2% in the equivalent metastatic tumour. 
Thus, a low activation state of PKB/Akt did not necessarily correlate with an equivalent 
activation state in its corresponding metastatic evolution. Figure 2D shows the Ef of 
different patients plotted as Box and Whiskers distributions. The median Ef differences 
between primary and metastatic tumour samples were compared to noncancerous renal 
control tissue. The non-parametric Mann-Witney U statistical tests illustrate a 
significant difference between the median of the Box and Whiskers plots of primary and 
metastatic tumours (p=3.81x10-5) and between metastatic and noncancerous control 
tissue (p=3.83x10-7). The Ef parameter was utilised as a variable to assess patient 
prognosis. The highest 25% and lowest 75% Ef values were used to plot the Kaplan-
Meier survival curves. Figure 3A shows that PKB/Akt activation state correlated with a 
poorer clinical outcome. The patients with the highest 25% of PKB/Akt activation were 
shown to have poorer prognoses when compared to the lower 75% (n=16, p=0.0018, 
HR = 0.22279 with 95% CI, 0.052- 1.005). When using intensity and protein expression 
as a method of analysis, a significant difference was not observed between the groups 
(n=16, p=0.5483, HR = 1.3912 with 95% CI, 0.484- 4.000). Figure 3B and 3C 
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summarise Mann-Whitney U tests performed on the primary ccRCC tumours. These 
statistical analyses determined the correlations between Ef or IHC methods (pThr308-
Akt-acceptor intensity) with histological grading (low (G1/2) and high (G3/4) grades) 
and staging (pT1/2 or pT3 in primary tumours). Neither A-FRET nor intensity 
determinations showed significant correlations with tumour grading or staging 
(confined versus not confined).   
 
DISCUSSION 
PKB/Akt is an oncoprotein, which is dysregulated in many human cancers [5]. Recently 
we have shown that its activation state is correlated to poor prognosis in breast cancer 
patients [4]. We also demonstrated that expression levels and activation states of 
oncoproteins did not necessarily correlate [4]. We therefore sought to assess whether in 
ccRCC patients, where the tyrosine kinase receptor pathways are dysregulated, 
PKB/Akt activation states would identify a worse clinical outcome. To validate this 
assessment, we constructed formalin-fixed paraffin embedded (FFPE) TMAs that 
included representative samples both of primary tumours and their metastases, either 
synchronic or metachronic, of 60 ccRCC patients with long-term clinical follow-up. A 
two-site time resolved amplified FRET method, detected by high throughput mfFLIM, 
was exploited to assess the functional state of PKB/Akt in these patients. Ef was utilised 
for determining the activation state of PKB/Akt [4]. Some differences in fluorescence 
lifetime occurred between donor only samples when comparing primary and metastatic 
samples; this is due to changes in the microenvironment between different tumours, 
such as pH and tissue type as metastatic tumours have the capability of creating a new 
tumour microenvironment in a range of tissue types. Comparisons between fluorescence 
lifetimes are made between donor and donor/acceptor samples of the same patient as 
these are tissues of the same type and from the same tumour microenvironment. 
  In summary, we have shown for the first time that the activation state of 
PKB/Akt in ccRCC patients, measured by A-FRET (but not by IHC intensity) was 
correlated with poorer overall survival. This assay is able to directly monitor the 
activation state of PKB/Akt in primary and metastatic ccRCC tissue, and could be used 
to monitor posttranslational modifications and complexes of other oncoproteins. The 
ability to accurately quantify the functional state of oncoproteins has important 
implications as a high number of ccRCCs, within their evolution, develop distant 
lymphatic and/or haematogenous metastases [17], whereby the prognostic impact of 
classical histologic features in the primary tumour diminishes or disappears. Here 
prognostic models turn to the prediction of response to systemic therapy [18]. Therefore, 
in such a context, companion diagnostics such as A-FRET will prove valuable.    
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FIGURE LEGENDS 
 
Figure 1-Schematic overview of the Protein Kinase B signalling pathway 
Protein Kinase B (PKB/Akt) is part of the AGC kinase super family. Upon the binding 
of a growth factor receptor to a receptor tyrosine kinase, phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2) is phosphorylated, by phosphoinositide 3-kinase (PI3K) to 
phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3). This recruits PKB and 
phosphoinositide-dependent protein kinase 1 (PDK1) to the plasma membrane. PDK1 
phosphorylates threonine-308 to partially active it and mTORC2 phosphorylates Ser473 
for full activation. 
 
 
Figure 2-PKB/Akt activation is higher in metastatic ccRCC tumours in FFPE 
TMAs. A, Low- (left) and high- (right) grade ccRCCs B, the intensity images 
(corresponding to protein expression levels) of PKB/Akt and pAkt expression levels do 
not yield differences. Lifetime maps however do yield significant differences between 
primary and metastatic ccRCC samples. C, PKB/Akt activation state determined by A-
FRET from primary to metastatic tumours for each patient. Patients 9 and 31 have 
higher Akt activation in their primary tumours D, the Box and Whisker plots show an 
increase in PKB/Akt activation from the non-tumour control tissue to the primary 
ccRCC cores with a significant difference of (p=3.81x10-5). Each point on the Box and 
Whisker plot indicates the activation state of the primary and metastatic tumours of each 
patient. A larger increase in activation is shown from primary cores to metastatic cores. 
P values are shown between significantly different groups.  
  
Figure 3-PKB/Akt activation state correlates with poor overall survival in ccRCC. 
A, shows the survival outcomes related to PKB/Akt activation as determined by A-
FRET (left panel) or by conventional IHC (right panel). A highly significant difference 
was observed between the upper quartile of FRET Efficiency and the lower 3 quartiles 
FRET Efficiency. No difference was detected when survival is determined by IHC 
intensity of the activation state of PKB/Akt. B, Both A-FRET and IHC detections did 
not relate to grading (High H and Low L) p=0.709 and p=0.968. C, A-FRET and IHC 
measurements did not show significant correlations between staging (confined, c, versus 
non-confined, n, primary tumours) p=0.774 and p=0.065 respectively. 
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Figure 2 
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Figure 3 
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Highlight 
Time Resolved Amplified FRET (A-FRET), has been used to quantitatively 
assess PKB/Akt activation states in ccRCC. Increased activation state of 
PKB/Akt in primary tumours was shown to correlate with poorer prognoses.  
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